# MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)

> **NCT04841811** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 192 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Almonertinib

## Key facts

- **NCT ID:** NCT04841811
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841811, "MDT-bridged Radical Therapy After Aumolertinib Introduction and Followed by MRD-guided Maintained Therapy for EGFR-mutated Unresectable Stage III NSCLC (APPROACH/CTONG2101)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04841811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*